Market Research Report
Global Digital Genome Market Forecast 2021-2028
|Published by||Inkwood Research||Product code||991382|
|Published||Content info||208 Pages
Delivery time: 2-3 business days
|Global Digital Genome Market Forecast 2021-2028|
|Published: March 1, 2021||Content info: 208 Pages||
The global digital genome market is set to record a CAGR of 9.43% during the forecast period, 2021-2028. The rising investment in genomics by governments and manufacturers, the increasing prevalence of chronic diseases, and technological advancements, are projected to propel the market growth.
The digital genome deals with genes and their functions. It is a set of genetic material in a cell. It aids in finding causes of chronic disorders and resolves them. There is a surge in chronic diseases worldwide. Twin studies have established genes as major contributors to chronic conditions like depression, diabetes, obesity, cardiovascular disease, RA, Alzheimer's disease (AD), etc. As per the WHO (World Health Organization), around 48800 died in the UK in 2015, due to chronic diseases. The hectic lifestyle has given rise to diabetes and conditions like acute myocardial infarction, angina pectoris, and atherosclerosis. According to the WHO, chronic diseases pose a massive global challenge, accounting for almost 60% of all deaths worldwide. The rising prevalence has resulted in the increased use of the digital genome to treat such conditions. In recent times, evaluating individual-level risks for chronic diseases using molecular genetic data has been enabled due to genetic sequencing. Such factors drive market growth.
The global digital genome market growth analysis entails the assessment of North America, Europe, Asia Pacific, and rest of world. The Asia Pacific is estimated to be the prominent region in terms of CAGR by 2028. The market prospects are attributed to the increasing investment and the advancing research & development in genomics.
The growing demand for digital genome has resulted in the entry of several pharmaceutical companies into the market for R&D purposes. Abbott Laboratories, BioMerieux SA, Agilent Technologies Inc, Bio-Rad Laboratories Inc, etc., are among the key players in the market.